How big is the Non-Alcoholic Steatohepatitis Market | Key Trends & Insights 2025

What is the size of Non-Alcoholic Steatohepatitis Market?

The market is expanding rapidly as obesity, type 2 diabetes, and sedentary lifestyles contribute to rising disease prevalence, while pharmaceutical advancements accelerate development of targeted therapies for liver inflammation and fibrosis.

Growth Factors for Non-Alcoholic Steatohepatitis Industry

• An increasing prevalence of obesity, metabolic syndrome, and type 2 diabetes is leading to an increase in disease incidence.
• Greater financial investments in clinical trials and biomarker research for early detection and intervention.
• Regulatory support and accelerated approvals for breakthrough therapies for liver fibrosis.
• A growing awareness among clinicians and patients on liver health and diagnostics.
• New and improved non-invasive diagnostics like imaging techniques and blood-based biomarkers are on the rise.

Non-Alcoholic Steatohepatitis Market Trends

The Non-Alcoholic Steatohepatitis Market is witnessing notable trends centered on personalized medicine, companion diagnostics, and combination therapies. Companies in the biopharmaceutical space focus on molecules that can target inflammation, fibrosis, and lipid metabolism that address the underlying mechanisms of the disease.

Trends also include utilization of artificial intelligence for early diagnosis, collaborations between diagnostic and pharma companies, and increasing interest in RNA-based therapies. Public-private partnerships and collaborations between industry and academia will continue to facilitate innovation and development.

Emerging Developments in the Non-Alcoholic Steatohepatitis Market

The Non-Alcoholic Steatohepatitis Market is seeing developments in fibrosis-targeting agents, metabolic modulators, and immune pathway inhibitors. FGF21 analogs, ACC inhibitors, and inhibitors of thyroid hormone receptor-β are currently being evaluated by drug developers associating them with possible new therapeutic avenues for treating liver disease.

Advances in non-invasive diagnostics, intended to lower reliance on the liver biopsy are also gaining traction. New clinical pipelines, orphan drug designations, and predictive analytics also show opportunities for companies to gain a competitive edge and reduce time-to-market.

List of Leading Companies in the Non-Alcoholic Steatohepatitis Market

Below is a comprehensive list of the leading market players driving growth in this sector:

1. Intercept Pharmaceuticals

Intercept is known for developing obeticholic acid (OCA), a therapy candidate targeting liver fibrosis in NASH patients.

2. Madrigal Pharmaceuticals

Madrigal is advancing MGL-3196 (Resmetirom), a selective thyroid hormone receptor-β agonist for NASH treatment.

3. Gilead Sciences

Gilead is developing multiple NASH candidates, including FGF21 analogs and FXR agonists for anti-fibrotic treatment.

4. Galmed Pharmaceuticals

Galmed is working on Aramchol, a liver-targeted drug modulating lipid metabolism and inflammation in NASH.

5. Genfit

Genfit is focused on NASH diagnostics and therapeutics, including elafibranor and biomarker-based testing.

6. Akero Therapeutics

Akero is advancing Efruxifermin, an FGF21 analog designed to improve insulin sensitivity and reduce liver fat.

7. 89bio Inc.

89bio develops biologic therapies for NASH, including pegozafermin targeting metabolic and fibrotic pathways.

8. Terns Pharmaceuticals

Terns is building a pipeline of monotherapies and combination treatments for NASH and related liver diseases.

9. Sagimet Biosciences

Sagimet is focused on fatty acid synthase inhibitors to treat underlying metabolic drivers of NASH.

10. Pfizer Inc.

Pfizer is pursuing strategic partnerships and NASH-specific programs targeting metabolic dysfunction and liver fibrosis.

How big is the Non-Alcoholic Steatohepatitis Market : FAQ's